Browse by Basel Contributors ID

No

Matter-Walstra, KW. and Szucs, T. and Brauchli, P. and Schwenkglenks, M.. (2008) Randomisiert-kontrollierte Studien von Krebstherapien in der Schweiz. Outcomes Research und gesundheitsökonomische Aspekte. Schweizerische Ärztezeitung, 89 (36). pp. 1545-1549.

Berberat, C. and Matter-Walstra, K. and Schöni-Affolter, F. and Künzi, B. and Busato, A.. (2007) Behandlungsqualität von Hausärzten in Einzel- und Gruppenpraxen der Schweiz. Schweizerische Ärztezeitung, 88 (42). pp. 1762-1768.

Matter-Walstra, K. and Widmer, M. and Schoeni-Affolter, F. and Balmer, C. and Busato, A.. (2007) Die medizinische Statistik für orthopädische Behandlungen. Schweizerische Ärztezeitung, 88 (45). pp. 1907-1908.

Matter-Walstra, K. and Widmer, M. and Schoeni-Affolter, F. and Balmer, C. and Busato, A.. (2007) Analyse der Hauptbehandlungskodierung der medizinischen Statistik für orthopädische Behandlungen mittels Spitaleinzugsgebieten (small area analysis). Schweizerische Ärztezeitung, 88 (45). pp. 1-8.

Matter-Walstra, K. W. and Künzi, B.. (2007) Ärztenetzwerke im Kanton Bern / nur Hoffnung oder die Realität von morgen? Schweizerische Ärztezeitung, 88 (44). pp. 1853-1862.

Matter-Walstra, K. W. and Hoffrage, U.. (2001) Individuelle Entscheidungsfindung am Beispiel der Brustkrebs-Früherkennung: Erfahrungen aus Fokusgruppen in der Schweiz. Care Management, 3 (5). pp. 26-29.

Yes

Panje, Cedric M. and Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Gautschi, Oliver and Siano, Marco and Aebersold, Daniel M. and Plasswilm, Ludwig and Lupatsch, Judith E.. (2018) A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 129. pp. 257-263.

Hirschmann, A. and Lupatsch, J. E. and Schwenkglenks, M. and Panje, C. M. and Matter-Walstra, K. and Espeli, V. and Dedes, K. J. and Siano, M.. (2018) Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral oncology, 87. pp. 104-110.

Matter-Walstra, Klazien Wietske and Schwenkglenks, Matthia and Dedes, Konstantin J.. (2017) Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast cancer research and treatment, 163 (3). p. 635.

Matter-Walstra, K. W. and Greiner, M. and Cusini, A. and Schiesser, M. and Ledergerber, B. and Fehr, T. and Mueller, N. J.. (2015) Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Transplant infectious disease, Vol. 17, H. 3. pp. 342-349.

Matter-Walstra, K. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2015) Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons : SAKK 89/09. Oncology, 88 (1). pp. 18-27.

Köberle, D. and Betticher, D. C. and von Moos, R. and Dietrich, D. and Brauchli, B. and Baertschi, D. and Matter, K. and Winterhalder, R. and Borner, M. and Anchisi, S. and Moosmann, P. and Kollar, A. and Saletti, P. and Roth, A. and Frueh, M. and Kueng, M. and Popescu, R. A. and Schacher, S. and Hess, V. and Herrmann, R.. (2015) Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology, 26 (4). pp. 709-714.

Kovacevic, A. and Dragojecic-Simic, V. and Rancic, N. and Jurisevic, M. and Gutzwiller, F. and Matter-Walstra, K. and Jakovljevic, M.. (2015) End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl, 72 (4). pp. 334-341.

Matter-Walstra, K. and Klingbiel, D. and Szucs, T. and Pestalozzi, B. C. and Schwenkglenks, M.. (2014) Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied? PharmacoEconomics, Vol. 32, no. 6. pp. 591-599.

Matter-Walstra, K. M. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Schwenkglenks, M. and Pestalozzi, B. C.. (2014) Delivery of health care at the end of life in cancer patients of four swiss cantons : a retrospective database study (SAKK 89/09). BMC cancer, Vol. 14. pp. 306-317.

Jakovljevic, Mihajlo and Gutzwiller, Florian S. and Schwenkglenks, Matthias and Milovanovic, Olivera and Rancic, Nemanja and Varjacic, Mirjana and Stojadinovic, Dobrivoje and Dagovic, Aleksandar and Matter-Walstra, Klazien. (2014) Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON, 19 (3). pp. 1111-1120.

Joerger, M. and Schaer-Thuer, C. and Koeberle, D. and Matter-Walstra, K. and Gibbons-Marsico, J. and Diem, S. and Thuerlimann, B. and Cerny, T.. (2014) Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. European Journal of Clinical Pharmacology, 70 (6). p. 719.

Matter-Walstra, Klazien and Joerger, Markus and Kühnel, Ursula and Szucs, Thomas and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2012) Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system. Value in health, Vol. 15, H. 1. pp. 65-71.

Joerger, Markus and Matter-Walstra, Klazien and Früh, Martin and Kühnel, Ursula and Szucs, Thomas D. and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of oncology, 22 (3). pp. 567-574.

Matter-Walstra, K. W. and Dedes, K. J. and Schwenkglenks, M. and Brauchli, P. and Szucs, T. D. and Pestalozzi, B. C.. (2010) Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21 (11). pp. 2161-2168.

Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Pestalozzi, Bernhard C. and Fink, Daniel and Brauchli, Peter and Szucs, Thomas D.. (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer : an economic evaluation. EJC : European journal of cancer, Vol. 45, H. 8. pp. 1397-1406.

Matter-Walstra, Klazien and Schoeni-Affolter, Franziska and Widmer, Marcel and Busato, André. (2008) Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine. Journal of Evaluation in Clinical Practice , 14 (1). pp. 75-82.

Schoeni-Affolter, F. and Matter-Walstra, K. and Widmer, M. and Busato, A.. (2007) Satisfaction with primary health care in patients with upper respiratory tract infection: a three-level approach. Complementary Medicine Research, 14 (6). pp. 346-352.

Matter-Walstra, K. and Widmer, M. and Busato, A.. (2006) Seasonal variation in orthopedic health services utilization in Switzerland: the impact of winter sport tourism. BMC Health Services Research, 6. p. 25.

Matter-Walstra, Klazien and Widmer, Marcel and Busato, André. (2006) Analysis of patient flows for orthopedic procedures using small area analysis in Switzerland. BMC Health Services Research, 6. p. 119.

Matter-Walstra, K. W. and Kraft, R.. (1996) Atypical cells in effusions: diagnostic value of cell image analysis combined with immunocytochemistry. Diagn Cytopathol, 15 (4). pp. 263-269.

Walstra, K. and Gratwohl, A. and Riederer, I. and Speck, B.. (1985) B/T cell ratio of rabbit peripheral blood lymphocytes : influence of separation technique on results. Journal of immunological methods, Vol. 79, H. 1. pp. 143-147.